SPOTLIGHT -
Enzalutamide shown to improve overall survival in hormone-sensitive prostate cancer
Patients received standard-of-care testosterone suppression with either oral enzalutamide or standard non-steroidal antiandrogen therapy.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
AI model able to generate high-quality synthetic prostate cancer MRIs
"The improvement in technologies could potentially assist radiation oncologists in making timely decisions,” said Himanshu Arora, PhD.
Dr. Laviana on decisional regret after prostate cancer treatment
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
How the ongoing shortage of 177Lu-PSMA-617 in the US affects care for patients with prostate cancer
"Some of these patients newly referred don't have any other proven therapies remaining...This is the only one on the shelf that has a proven benefit. Unfortunately, we can't offer them that at this stage," says Praful Ravi, MD, BChir, MRCP.
Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry
Researchers identified 9 novel susceptibility loci for prostate cancer, 7 of which were substantially more prevalent in patients of African ancestry.
